Clinical Trial Goal
To find out if the enasidenib, alone or in combination with rituximab, is safe and works well to treat IDH2+ AITL
You may be able to join this trial if you:
- Are 18 years old or older
- Have AITL
- Have cancer cells with IDH2 mutation. Your doctor can tell you this
- Have not been treated with enasidenib. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Enasidenib is a small molecule inhibitor that blocks IDH2 in certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
In this trial, you’ll be placed in 1 of 2 groups depending on your diagnosis:
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
In this trial, you’ll be placed in 1 of 2 groups depending on your diagnosis:
- Group 1 – enasidenib
- Group 2 – enasidenib plus rituximab
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Enasidenib – A pill that you take by mouth 1 time each day
- Rituximab - Group 2 only - Given as intravenous (IV) infusions up to 4 times
You may continue treatment for up to 4 months. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat IDH2+ AITL is new and unproven.
Contacts
Zachary Epstein-Peterson, MD, 646-608-4176, epsteinz@mskcc.org
Steven Horwitz, MD, 646-608-3725
Locations
Sponsors
collaborator: Bristol-Myers Squibb, collaborator: The Leukemia and Lymphoma Society, lead: Memorial Sloan Kettering Cancer Center
